Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics
Authors:
- Arvin BehzadiABArvin Behzadi
- Fani Pujol-CalderónFPFani Pujol-Calderón
- Anton E. TjustATAnton E. Tjust
- Anna WuolikainenAWAnna Wuolikainen
- Kina HöglundKHKina Höglund
- Karin ForsbergKFKarin Forsberg
- Erik PorteliusEPErik Portelius
- Kaj BlennowKBKaj Blennow
- Henrik ZetterbergHZHenrik Zetterberg
- Peter Munch AndersenPAPeter Munch Andersen
Open Access
- 11 November 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-12
Abstract
Delayed diagnosis and misdiagnosis are frequent in people with amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease (MND). Neurofilament light chain (NFL) and phosphorylated neurofilament heavy chain (pNFH) are elevated in ALS patients. We retrospectively quantified cerebrospinal fluid (CSF) NFL, CSF pNFH and plasma NFL in stored samples that were collected at the diagnostic work-up of ALS patients (n = 234), ALS mimics (n = 44) and controls (n = 9). We assessed the diagnostic performance, prognostication value and relationship to the site of onset and genotype. CSF NFL, CSF pNFH and plasma NFL levels were significantly increased in ALS patients compared to patients with neuropathies & myelopathies, patients with myopathies and controls. Furthermore, CSF pNFH and plasma NFL levels were significantly higher in ALS patients than in patients with other MNDs. Bulbar onset ALS patients had significantly higher plasma NFL levels than spinal onset ALS patients. ALS patients withC9orf72HRE mutations had significantly higher plasma NFL levels than patients with SOD1 mutations. Survival was negatively correlated with all three biomarkers. Receiver operating characteristics showed the highest area under the curve for CSF pNFH for differentiating ALS from ALS mimics and for plasma NFL for estimating ALS short and long survival. All three biomarkers have diagnostic value in differentiating ALS from clinically relevant ALS mimics. Plasma NFL levels can be used to differentiate between clinical and genetic ALS subgroups.Keywords
Funding Information
- Region Västernorrland (LVNFOU939000)
- Horizon 2020 (633413, 860197)
- Hjärnfonden (2012-0262, 2012-0305, 2013-0279, 2016-0303, 2020-0353)
- the Ulla-Carin Lindquist Foundation
- Alzheimer's Drug Discovery Foundation (RDAPB-201809-2016615)
- EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
- swedish alzheimer foundation (AF-742881)
- Knut och Alice Wallenbergs Stiftelse (2012.0091, 2014.0305, 2020.0232)
- Vetenskapsrådet (2012-0262, 2012-0305, 2013-0279, 2016-0303, 2020-0353)
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Umea University
This publication has 59 references indexed in Scilit:
- Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological DiseasesPLOS ONE, 2013
- Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2012
- The C-Terminal Domains of NF-H and NF-M Subunits Maintain Axonal Neurofilament Content by Blocking Turnover of the Stationary Neurofilament NetworkPLOS ONE, 2012
- EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task forceEuropean Journal of Neurology, 2011
- Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALSJournal of Neurochemistry, 2011
- A novel SOD1 splice site mutation associated with familial ALS revealed by SOD activity analysisHuman Molecular Genetics, 2010
- Study of 962 patients indicates progressive muscular atrophy is a form of ALSNeurology, 2009
- Amyotrophic lateral sclerosisOrphanet Journal of Rare Diseases, 2009
- Prognostic factors in ALS: A critical reviewAmyotrophic Lateral Sclerosis, 2009
- EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relativesEuropean Journal of Neurology, 2005